Drug delivery formulations
The present invention is directed to methods of treating psychiatric diseases and disorders comprising administering to a subject in need thereof an injectable formulation comprising risperidone, triblock and diblock copolymers wherein the concentration of the risperidone is 250-400 mg/mL and injection volume is 1 mL or less.
1. A method of treating a psychiatric disease or disorder in a subject, comprising subcutaneously administering to the subject with a frequency of no more than once every 21 days:
0.1 mL to 0.8 mL of a pharmaceutical formulation comprising:
a) risperidone, or a pharmaceutically acceptable salt thereof, at a concentration of about 300-400 mg/mL, equivalent to risperidone;
b) a biodegradable triblock copolymer having the formula: poly(lactic acid)v-poly(ethylene glycol)w,-poly(lactic acid)x
wherein v and x are the number of repeat units ranging from 24 to 682 and w is the number of repeat units ranging from 4 to 273 and v-x or v #x;
c) a biodegradable diblock copolymer having the formula: methoxy poly(ethylene glycol)y-poly(lactic acid)z,
wherein y and z are the number of repeat units, wherein y is the number of repeat units ranging from 3 to 45 and z is the number of units ranging from 7 to 327;
wherein the ratio of the biodegradable triblock copolymer of (b) and the biodegradable diblock copolymer of (c) is 1:3 to 1:8 or 1:1 to 1:19 or 3:2 to 1:19, in said formulation, which is insoluble in an aqueous environment and
wherein the triblock copolymer is present in an amount of about 5% to 15% (w/w %) of the total weight of the formulation, the diblock copolymer is present in an amount of about 10% to 20% (w/w %) of the total weight of the formulation and the triblock and diblock copolymers together are present in a total amount of about 20% to 30% (w/w %) of the total weight of the formulation.
2. The method of claim 1 , wherein the risperidone is risperidone base.
3. The method of claim 1 , wherein the formulation further comprises a water soluble organic solvent that is DMSO.
4. The method of claim 3 , wherein the formulation further comprises triacetin, tripropionin, or a mixture thereof.
5. The method of claim 3 , wherein the organic solvent is present in an amount of about 35% to about 55% (w/w %) of the total weight of the formulation.
6. The method of claim 1 , wherein the administration is effective in treating the subject's psychiatric disease or disorder for 21 days to 90 days.
7. The method of claim 1 , wherein the administration is effective in treating the subject's psychiatric disease or disorder for 28 days to 90 days.
8. The method of claim 1 , wherein the administration is effective in treating the subject's psychiatric disease or disorder for 28 days to 56 days.
9. The method of claim 1 , wherein less than about 15 w % of the risperidone in the formulation is cumulatively released at 24 hours post administration.
10. The method of claim 9 , wherein about 7 w % to about 15 w % of the risperidone in the formulation is cumulatively released at 24 hours post administration.
11. The method of claim 6 , wherein about 50 w % to about 80 w % of the risperidone in the formulation is cumulatively released at 30 days post administration.
12. The method of claim 6 , wherein about 70 w % to about 98% w % of the risperidone in the formulation is cumulatively released at 60 days administration.
13. The method of claim 9 , wherein the cumulative release is determined by in vitro release (IVR) method disclosed herein.
14. The method of claim 1 , wherein the psychiatric disease or disorder is schizophrenia or bipolar disorder.
15. The method of claim 1 , wherein the method is implemented in the absence of a loading dose or supplemental oral risperidone.
16. The method of claim 1 for implementation over a period of at least 6 months.
17. The method of claim 16 , for implementation over a period of at least 15 months.
18. The method of claim 1 , wherein the formulation is presented in a single prefilled syringe (PFS).
19. The method of claim 1 , for subcutaneous administration into the abdomen.
20. The method of claim 1 , for subcutaneous administration into the upper arm.
21. The method of claim 1 , wherein the formulation is excisable following administration into the subject.
22. A pharmaceutical formulation comprising 0.1 mL to 0.8 mL of:
a) risperidone, or a pharmaceutically acceptable salt thereof, at a concentration of about 300-400 mg/mL, equivalent to risperidone;
b) a biodegradable triblock copolymer having the formula: poly(lactic acid)v-poly(ethylene glycol)w,-poly(lactic acid)x wherein v and x are the number of repeat units ranging from 24 to 682 and w is the number of repeat units ranging from 4 to 273 and v=x or v≠x;
c) a biodegradable diblock copolymer having the formula: methoxy poly(ethylene glycol)y-poly(lactic acid)z,
wherein y and z are the number of repeat units, wherein y is the number of repeat units ranging from 3 to 45 and z is the number of units ranging from 7 to 327;
wherein the ratio of the biodegradable triblock copolymer of (b) and the biodegradable diblock copolymer of (c) is 1:3 to 1:8 or 1:1 to 1:19 or 3:2 to 1:19, in said formulation, which is insoluble in an aqueous environment, and
wherein the triblock copolymer is present in an amount of about 5% to 15% (w/w %) of the total weight of the formulation, the diblock copolymer is present in an amount of about 10% to 20% (w/w %) of the total weight of the formulation and the triblock and diblock copolymers together are present in a total amount of about 20% to 30% (w/w %) of the total weight of the formulation for use in treating a psychiatric disease or disorder.
23. The method of claim 1 , wherein the triblock copolymer is present in an amount of about 5% to 10% (w/w %) of the total weight of the formulation.
24. The pharmaceutical formulation of claim 22 , wherein the triblock copolymer is present in an amount of about 5% to 10% (w/w %) of the total weight of the formulation.